Fact Meets Function

A phase 1/2 clinical trial showed that low-dose oral NMN (450mg twice daily for 2 weeks) was safe and well-tolerated in 25 patients with steroid-resistant immune thrombocytopenia (ITP), with no serious adverse events. The study found that 20% of patients achieved the primary endpoint of platelet recovery, while 60% showed meaningful platelet count improvements. The mechanism involves NMN restoring NAD+ levels, which reprograms immune macrophages to reduce their destruction of platelets while preserving normal immune function.

This review examines NAD+ (nicotinamide adenine dinucleotide) as a critical cellular energy cofactor and its role in cardiovascular health. NAD+ levels naturally decline with age and disease, contributing to cardiovascular dysfunction. The review likely covers how NAD+ supplementation through precursors like NMN may help restore cellular energy metabolism and support heart health. This positions NAD+ enhancement as a therapeutic target for cardiovascular disease prevention and treatment.

This study demonstrates that acidic cellular environments deplete NAD+ levels and cause mitochondrial dysfunction, but NMN supplementation can partially rescue these effects. The research provides mechanistic evidence for how NMN works at the cellular level, particularly in restoring NAD+ levels and reversing mitochondrial DNA damage. This gives practitioners scientific backing for NMN’s role in cellular health and metabolic function, especially in patients with inflammatory conditions or metabolic stress.

A new study in European Heart Journal shows that declining NAD+ levels with age contribute to calcific aortic valve disease by disrupting cellular metabolism and promoting inflammation. This research provides mechanistic support for NAD+ supplementation in cardiovascular aging, directly validating the therapeutic rationale for NMN. The findings suggest NAD+ restoration could help prevent or slow progression of this common age-related heart condition that currently lacks effective drug treatments.

A phase I clinical trial found that oral NMN supplementation at 1,200 mg/day effectively increases NAD levels in both blood and brain tissue, with benefits requiring 2-4 weeks of sustained administration. The study showed once-daily dosing is sufficient and works equally well in healthy individuals and Parkinson’s patients. This provides clinical validation for NMN’s bioavailability and establishes evidence-based dosing protocols that practitioners can reference when prescribing Annular’s NMN product.

This veterinary study demonstrates that oral NMN supplementation significantly reduces elevated NT-proBNP levels (a cardiac dysfunction biomarker) in dogs with preserved cardiac structure or mild-to-moderate elevation, likely through improved mitochondrial energy metabolism. NMN showed limited efficacy in severe heart disease and required combination with conventional therapy in complex cases. The findings suggest NMN has potential as an adjunctive cardioprotective agent in veterinary practice, though further controlled studies are needed to establish its clinical role.